Welcome to our dedicated page for Retractable Tech news (Ticker: RVP), a resource for investors and traders seeking the latest updates and insights on Retractable Tech stock.
Retractable Technologies, Inc. reports developments tied to its safety medical products business, including VanishPoint® syringes, blood collection and IV catheter products, Patient Safe® syringes, and EasyPoint® retractable needles. The company manufactures and markets devices designed to reduce needlestick injuries, product reuse, and catheter-related contamination risks, with distribution through specialty and general line medical distributors.
Recurring news themes for RVP include operating results, domestic and international sales trends, product mix shifts involving EasyPoint® needles, tariff exposure on products imported from China, and changes in manufacturing activity as the company expands domestic production where practical. Updates also cover workforce reductions, product designations, and dividends on Series II and Series III Class B Convertible Preferred Stock.
Retractable Technologies (NYSE American:RVP) reported Q1 2026 net sales of $7.2 million and an operating loss of $6.2 million, versus $8.3 million and a $4.7 million loss a year earlier.
Unit sales grew 3.6%, tariffs dropped to about $11.6 thousand, operating expenses rose 14%, net loss was $4.2 million, and a 16% April workforce reduction is expected to save $2.2 million annually.
Retractable Technologies (NYSE: RVP) said it reduced its workforce by approximately 16% on April 9, 2026, targeting about $2.2 million in annual wage and benefit savings, equal to roughly 13% of total workforce costs.
One-time separation payments are estimated at $122,000. About 58% of reductions affect manufacturing and manufacturing support while the company shifts production domestically to mitigate tariff costs on imports from China, but it remains reliant on some Chinese-sourced products.
Retractable Technologies (NYSE American: RVP) reported 2025 results for year ended December 31, 2025. Revenue rose 15.8% to $38.3 million, driven by domestic VanishPoint® and EasyPoint® sales and a 64.0% jump in international revenue.
The company recorded a $21.2 million loss from operations and total operating expenses of $21.2 million. Cash decreased $1.6 million to $2.6 million at year-end, and the company held $34.4 million in debt and equity securities. Tariff expense totaled $1.8 million; 62.6% of product sourcing was from China and prevailing tariffs were 120% as of March 9, 2026. Management expects tariffs will materially affect operations.
Retractable Technologies (NYSE American: RVP) declared dividends to holders of its Series II Class B and Series III Class B convertible preferred stock totaling $39,050.00 and $18,561.25, respectively.
Dividends accrue at $1.00 per share per annum, cover Jan 1, 2026–Mar 31, 2026, will be paid on April 20, 2026, to holders of record as of April 10, 2026. Retractable manufactures VanishPoint®, Patient Safe®, and EasyPoint® safety medical products.
Retractable Technologies (NYSE American: RVP) declared cash dividends to holders of its Series II Class B and Series III Class B convertible preferred stock totaling $39,050.00 and $18,561.25, respectively.
Dividends accrued at $1.00 per share per annum for the period October 1, 2025 through December 31, 2025. Payment is scheduled for January 20, 2026 to shareholders of record as of the close of business on January 10, 2026.
Retractable manufactures safety medical products including VanishPoint, Patient Safe, and EasyPoint and distributes them through specialty and general line distributors.
Retractable Technologies (NYSE: RVP) reported Q3 2025 net sales of $10.1M and an operating loss of $3.7M, versus $10.3M sales and a $5.1M operating loss in Q3 2024. For the nine months ended September 30, 2025, net sales were $28.8M and operating losses were $13.5M, compared with $24.0M revenue and $13.9M operating loss in 2024.
Tariffs materially affected results: a 130% tariff on needles and syringes from China and 30% on other Chinese imports; tariffs totaled $2.3M in the first nine months of 2025. The company shifted production to the U.S. (38.3% of products U.S.-made in YTD 2025 vs 10% in 2024) and took workforce reductions.
Q3 net income was $0.37M including $2.4M unrealized investment gains; YTD net loss was $10.2M including $3.2M unrealized losses and a $1.9M litigation settlement.
Retractable Technologies (NYSE: RVP) announced its EasyPoint® Blood Collection Tube Holder with Needle received an Innovative Technology designation from Vizient on November 14, 2025. Vizient's client-led councils designate previously contracted products that may enhance clinical care, patient safety, worker safety, or healthcare operations.
The EasyPoint BCTH uses automated in-vein retraction, a pre-attached needle, an integrated low-profile safety mechanism, and one-handed activation to reduce needlestick exposure, streamline workflow, and render the device non-reusable once activated.
Retractable Technologies (NYSE American: RVP) has declared quarterly dividends for its Series II and Series III Class B Convertible Preferred Stock shareholders. The company will pay $39,050.00 to Series II holders and $18,561.25 to Series III holders, reflecting an accrual rate of $1.00 per share per annum for Q3 2025.
The dividends will be paid on October 20, 2025 to shareholders of record as of October 10, 2025. Retractable Technologies specializes in manufacturing safety medical products including VanishPoint®, Patient Safe®, and EasyPoint® needle products designed to prevent needlestick injuries and reduce infection risks.
Retractable Technologies (NYSE American: RVP) reported Q2 2025 financial results, with total net sales of $10.4 million, up from $6.0 million in Q2 2024, despite an operating loss of $5.1 million. For H1 2025, net sales reached $18.7 million, compared to $13.6 million in H1 2024, with operating losses of $9.8 million.
The company faces significant challenges from Chinese import tariffs of 130% on needles and syringes, spending $2.1 million on tariffs in H1 2025. In response, RVP has increased U.S. production to 38% of total manufacturing, up from 9% in 2024. The company implemented workforce reductions to offset higher domestic manufacturing costs. A notable $1.9 million litigation settlement was received in Q2 2025, while the company recorded an unrealized loss of $5.6 million on investments.
Retractable Technologies (NYSE American: RVP) has announced a 12.4% reduction in its manufacturing workforce. The company expects to save approximately $1.6 million in annual wages and benefits, representing an 8.6% reduction in total workforce costs, offset by one-time separation payments of $56,000.
The workforce reduction primarily affects manufacturing and support positions as RVP balances domestic production against Chinese imports. The decision comes as the company grapples with significant tariff impacts on Chinese imports, leading to increased focus on domestic production at its Little Elm facility while continuing to import only products that cannot be manufactured domestically.